Basic Information

Common Name
B-hCD20 MC38
Catalog number
MS4A1, Bp35, CVID5
Colon carcinoma
Tissue types
B-hCD20 MC38 cells have the capability to establish tumors in vivo and can be used for efficacy studies.


The human CD20 coding sequence was inserted into the ROSA26 locus in MC38 cells. Human CD20 is highly expressed on the surface of B-hCD20 MC38 cells.

Protein expression analysis

CD20 expression analysis in B-hCD20 MC38 cells by flow cytometry. Single cell suspensions from wild-type MC38 and B-hCD20 MC38 cultures were stained with species-specific anti-CD20 antibody. Human CD20 was detected on the surface of B-hCD20 MC38 cells but not wild-type MC38 cells. The 2-A12 clone of B-hCD20 MC38 cells was used for in vivo experiments.

Tumor growth curve & Body weight changes

Subcutaneous homograft tumor growth of B-hCD20 MC38 cells. B-hCD20 MC38 cells and wild-type MC38 cells were subcutaneously implanted into C57BL/6 mice (female, 8-week-old, n=5). Tumor volume and body weight were measured twice a week. (A) Average tumor volume ± SEM. (B)  Body weight (Mean± SEM). Volume was expressed in mm3 using the formula: V=0.5 X long diameter X short diameter2. As shown in panel A, B-hCD20 MC38 cells were able to establish tumors in vivo and can be used for efficacy studies.

The subcutaneous tumor formation of B-hCD20 MC38 cells was slow, and the inoculation dose was recommended to be increased to 1×107.

Protein expression analysis of tumor cells

B-hCD20 MC38 cells were subcutaneously transplanted into C57BL/6 mice (n=5). At the end of the experiment, tumor cells were harvested and assessed for human CD20 expression by flow cytometry. As shown, human CD20 was expressed on the surface of tumor cells. Therefore, B-hCD20 MC38 cells can be used for in vivo efficacy studies of novel CD20 therapeutics.

Back to top